Skip to main content

ORIGINAL RESEARCH article

Front. Neurol.
Sec. Multiple Sclerosis and Neuroimmunology
Volume 15 - 2024 | doi: 10.3389/fneur.2024.1474888
This article is part of the Research Topic Neuroimaging Innovations for Encephalitis, Neuroinfectious Diseases, and Neuroinflammation View all 3 articles

Clinical characteristics and prognosis analysis of acute symptomatic seizures secondary to autoimmune encephalitis

Provisionally accepted
  • 1 Ningxia Medical University, Yinchuan, Ningxia, China
  • 2 General Hospital of Ningxia Medical University, Yinchuan, Ningxia Hui Region, China

The final, formatted version of the article will be published soon.

    Objective:This study aimed to analyze the clinical characteristics and prognosis of patients with AE (PWAE) who experienced seizures during the acute phase.Methods:Clinical data were collected from 84 patients diagnosed with AE at the General Hospital of Ningxia Medical University between January 2015 and January 2023. Patients were divided into seizure and non-seizure groups. Clinical characteristics of both groups were compared, including differences between anti-NMDAR and anti-LGI1 encephalitis within the seizure group. Due to the limited sample size and to avoid overfitting, we focused on univariate logistic regression analysis to identify individual prognostic factors.Results:A total of 84 patients were enrolled, with 76.19% (64/84) in the seizure group and 23.81% (20/84) in the non-seizure group. The seizure group had a longer hospital stay (P=0.013), higher rates of impaired consciousness (P=0.001), and more frequent intensive care unit (ICU) admission (P=0.011). They also had higher peripheral blood neutrophil-to-lymphocyte ratio (NLR), leukocyte count, and uric acid levels (P=0.038, P=0.006, P=0.020), and were more likely to show slow-wave rhythms on electroencephalography (EEG) (P=0.031). At 2-year follow-up, there was no significant difference in prognosis between the seizure and non-seizure groups (P=0.653), with 35.94% (23/64) of the seizure group having a poor prognosis. Status epilepticus (SE), complications, endotracheal intubation, mRS score at discharge, APE 2 , and RITE 2 scores increased the risk of poor prognosis (OR > 1), while intensive care and albumin reduced the risk (OR < 1).Seizures are common in the early stages of AE, with faciobrachial dystonic seizures (FBDS) characteristic of anti-LGI1 encephalitis and SE and super-refractory status epilepticus (Sup-RSE) frequently observed in anti-NMDAR encephalitis. Seizure semiology across AE subtypes lacks specificity, and no symptoms clearly distinguish immune-mediated from non-immune causes. While seizures are linked to AE severity, particularly in anti-NMDAR encephalitis, they do not appear to impact overall prognosis. SE, complications, endotracheal intubation, modified Rankin Scale (mRS) score at discharge, Antibody-Prevalence in Epilepsy and Encephalopathy (APE 2 ) score, Response to Immunotherapy in Epilepsy and Encephalopathy (RITE 2 ) score, intensive care, and albumin were identified as significant prognostic factors.

    Keywords: autoimmune encephalitis(AE), seizure, Clinical Characteristics, prognosis, NLR

    Received: 02 Aug 2024; Accepted: 15 Oct 2024.

    Copyright: © 2024 Li, Zhang, Wang, Tan and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Qing Zhang, General Hospital of Ningxia Medical University, Yinchuan, Ningxia Hui Region, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.